{"analyses":[{"ciLowerLimit":"0.11","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.38","estimateComment":"A hazard ratio \\< 1 favours osimertinib","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.21","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA - Not calculated as median not reached and insufficient number of events to enable upper limit of 95% confidence interval to be calculated","groupId":"OG000","lowerLimit":"39.29","upperLimit":"NA","value":"NA"},{"comment":"NA - Not calculated as insufficient number of events to enable upper limit of 95% confidence interval to be calculated","groupId":"OG001","lowerLimit":"9.03","upperLimit":"NA","value":"13.04"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Time from the date of randomisation until the first date of distant metastases or date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is detected on a scan that is anywhere other than lung or regional lymph node according to RECIST v1.1 or proven by biopsy","dispersionType":"95% Confidence Interval","groups":[{"description":"80mg once daily tablet","id":"OG000","title":"Osimertinib"},{"description":"Matching Placebo","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Time from randomisation to the date of distant metastases or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months","title":"Time to Death or Distant Metastases by Blinded Independent Central Review (BICR)","type":"SECONDARY","unitOfMeasure":"Months"}